The Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of a Nosocomial Outbreak of HCV in Patients with Significant Cardiovascular Disease

Abstract

Background

There is an unmet need for interferon-and ribavirin-free treatment for chronic HCV infection in patients with comorbidities including cardiovascular disease (CVD). The aim of this study was to evaluate the rates of sustained virological response (SVR) and adverse events in a cohort of patients with nosocomially acquired HCV genotype-1b following 12 weeks of therapy with fixed-dose combination (FDC) ledipasvir/ sofosbuvir (LDV/SOF).

Methods

This is a prospective, single-centre, open-label study of five non-cirrhotic patients with HCV genotype-1b and significant comorbid CVD, conducted at the Massachusetts General Hospital. All patients were prescribed an FDC tablet (LDV 90 mg/SOF 400 mg) once daily for 12 weeks. Serial measurements of safety parameters, virology, host immune correlates and adherence were performed. The primary outcome was the proportion of patients with SVR (plasma HCV RNA level <25 IU/ml), 12 weeks after treatment completion (SVR12).

Results

All five patients (100%) achieved SVR12, with no episodes of on- or post-treatment relapse. The most commonly reported adverse events were gastrointestinal illness and upper respiratory viral-type illness. There were no serious adverse events or discontinuations of medication attributable to the study drug. Deep sequencing analysis revealed no baseline NS3, NS5A or NS5B resistance-associated variants.

Conclusions

In this open-label, uncontrolled, pilot study enrolling patients with HCV genotype-1b and significant CVD, administration of a fixed-dose, oral combination of LDV and SOF for 12 weeks was associated with high rates of SVR and minimal adverse events. Larger prospective studies that also include patients with cirrhosis and prior treatment non-responders are necessary.

References

Hajarizadeh

, Grebely

, Dore

G.J.

Epidemiology and natural history of HCV infection.

Nat Rev Gastroenterol Hepatol 2013; 10: 553–562.

Chou

R.H.D.

, Rahman

, Wasson

, Cottrell

, Fu

Treatment for hepatitis C virus infection in adults. Comparative Effectiveness Review No 76. (Accessed 3 August 2015.) Available from http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0051681/pdf/PubMedHealth_PMH0051681.pdf.

Manns

M.P.

, McHutchison

J.G.

, Gordon

S.C.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Lancet 2001; 358: 958–965.

Fried

M.W.

, Shiffman

M.L.

, Reddy

K.R.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

N Engl J Med 2002; 347: 975–982.

Fried

M.W.

Side effects of therapy of hepatitis C and their management.

Hepatology 2002; 36 Suppl 1: S237–S244.

Gara

, Ghany

M.G.

What the infectious disease physician needs to know about pegylated interferon and ribavirin.

Clinical Infect Dis 2013; 56: 1629–1636.

FDA antiviral drugs advisory committee meeting, sofosbuvir (GS-7977). (Accessed 3 October 2015.) Available from http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/ucm371875.htm.

Kowdley

K.V.

, Lawitz

, Crespo

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre Phase 2 trial.

Lancet 2013; 381: 2100–2107.

Lawitz

, Mangia

, Wyles

Sofosbuvir for previously untreated chronic hepatitis C infection.

N Engl J Med 2013; 368: 1878–1887.

10.

Lawitz

, Poordad

F.F.

, Pang

P.S.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, Phase 2 trial.

Lancet 2014; 383: 515–523.

11.

Afdhal

, Zeuzem

, Kwo

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

N Engl J Med 2014; 370: 1889–1898.

12.

Afdhal

, Reddy

K.R.

, Nelson

D.R.

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

N Engl J Med 2014; 370: 1483–1493.

13.

Kowdley

K.V.

, Gordon

S.C.

, Reddy

K.R.

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

N Engl J Med 2014; 370: 1879–1888.

14.

Gilead Sciences. Harvoni prescribing information. (Accessed 2 September 2015.) Available from http://www.gilead.com/∼/media/files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf.

15.

Gane

E.J.

, Stedman

C.A.

, Hyland

R.H.

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

Gastroenterology 2014; 146: 736–743.

16.

Ghany

M.G.

, Strader

D.B.

, Thomas

D.L.

, Seeff

L.B.

American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update.

Hepatology 2009; 49: 1335–1374.

17.

Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 2.0. In: U.S. Department of Health and Human Services NIoH, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS). Version 2.0 (November 2014). (Accessed 2 October 2015.) Available from http://rsc.tech-res.com/Document/safetyandpharmacovigilance/DAIDS_AE_Grading_Table_v2_NOV2014.pdf.

18.

Ward

, Lauer

, Isba

, Walker

, Klenerman

Cellular immune responses against hepatitis C virus: the evidence base 2002.

Clin Exp Immunol 2002; 128: 195–203.

19.

Lauer

G.M.

, Ouchi

, Chung

R.T.

Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities.

J Virol 2002; 76: 6104–6113.

20.

Hedskog

, Doehle

, Chodavarapu

Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin.

Hepatology 2015; 61: 471–480.

21.

Cox

A.L.

, Mosbruger

, Lauer

G.M.

, Pardoll

, Thomas

D.L.

, Ray

S.C.

Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

Hepatology 2005; 42: 104–112.

22.

Fujino

, Imamura

, Nagaoki

Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.

J Gastroenterol 2014; 49: 1548–1556.

23.

Recommendations for Testing, Managing, and Treating Hepatitis C. (Accessed 11 October 2015.) Available from www.hcvguidelines.org.

24.

Hsu

Y.C.

, Lin

J.T.

, Ho

H.J.

Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.

Hepatology 2014; 59: 1293–1302.

25.

van der Meer

A.J.

, Veldt

B.J.

, Feld

J.J.

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

JAMA 2012; 308: 2584–2593.

26.

Chew

K.W.

, Hua

, Bhattacharya

The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection.

Open Forum Infect Dis 2014; 1: ofu104.

27.

Backus

L.I.

, Boothroyd

D.B.

, Phillips

B.R.

, Belperio

, Halloran

, Mole

L.A.

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

Clin Gastroenterol Hepatol 2011; 9: 509–516.

28.

Innes

H.A.

, McDonald

S.A.

, Dillon

J.F.

Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.

Hepatology 2015; 62: 355–364.

29.

Freeman

A.J.

, Dore

G.J.

, Law

M.G.

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

Hepatology 2001; 34: 809–816.

30.

Furusyo

, Ogawa

, Nakamuta

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.

J Hepatol 2013; 59: 205–212.

31.

Colombo

, Fernandez

, Abdurakhmanov

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.

Gut 2014; 63: 1150–1158.

32.

Colombo

, Strasser

, Moreno

Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.

J Hepatol 2014; 61: 976–983.

33.

Zeuzem

, Dusheiko

G.M.

, Salupere

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

N Engl J Med 2014; 370: 1993–2001.

34.

Sulkowski

M.S.

, Naggie

, Lalezari

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

JAMA 2014; 312: 353–361.

35.

Mangia

, Piazzolla

Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies.

Dig Liver Dis 2014; 46 Suppl 5: S179–185.

36.

Mangia

A.K.M.

, Kugelmas

, Everson

Virologic response rates to Sofosbuvir-containing regimens are similar in patients with and without traditional negative predictive factors: a retrospective analysis of Phase 3 data. Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 1–5 November 2013, Washington, DC, USA. Abstract 1115.

37.

Manns

, Pol

, Jacobson

I.M.

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, Phase 3, multicohort study.

Lancet 2014; 384: 1597–1605.